Literature DB >> 19901088

Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.

S Faure1, A Perrin-Guyomard, J M Delmas, P Chatre, M Laurentie.   

Abstract

Food animals are a potential source of CTX-M resistance genes for humans. We evaluated the transfer of the bla(CTX-M-9) gene from an animal strain of Salmonella enterica serotype Virchow to Enterobacteriaceae of the human intestinal flora by using human flora-associated (HFA) rats with and without cefixime treatment. In the absence of antibiotic, no transconjugant enterobacteria were found in the feces of HFA rats. However, the transfer rate was high if Escherichia coli J5 recipient strains were coinoculated orally with Salmonella. S. enterica serotype Virchow persisted in the rat fecal flora both during and after treatment with therapeutic doses of cefixime. The drug did not increase the transfer rate, and E. coli J5 transconjugants were eliminated from the flora before the end of cefixime treatment. No cefixime was recovered in the rat feces. In the presence of recipient strains, the bla(CTX-M-9) resistance gene was transferred from a strain of animal origin to the human intestinal flora, although transconjugant colonization was transient. Antibiotic use enhanced the persistence of donor strains, increasing the resistance gene pool and the risk of its spread.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901088      PMCID: PMC2798505          DOI: 10.1128/AAC.00310-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

2.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage).

Authors:  Raúl Jesús Mesa; Vanessa Blanc; Anicet R Blanch; Pilar Cortés; Juan José González; Susana Lavilla; Elisenda Miró; Maite Muniesa; Montserrat Saco; Ma Teresa Tórtola; Beatriz Mirelis; Pere Coll; Montserrat Llagostera; Guillem Prats; Ferran Navarro
Journal:  J Antimicrob Chemother       Date:  2006-05-23       Impact factor: 5.790

Review 3.  An epidemic of plasmids? Dissemination of extended-spectrum cephalosporinases among Salmonella and other Enterobacteriaceae.

Authors:  Lin-Hui Su; Chishih Chu; Axel Cloeckaert; Cheng-Hsun Chiu
Journal:  FEMS Immunol Med Microbiol       Date:  2007-12-18

4.  Clonal emergence of extended-spectrum beta-lactamase (CTX-M-2)-producing Salmonella enterica serovar Virchow isolates with reduced susceptibilities to ciprofloxacin among poultry and humans in Belgium and France (2000 to 2003).

Authors:  Sophie Bertrand; François-Xavier Weill; Axel Cloeckaert; Martine Vrints; Eric Mairiaux; Karine Praud; Katlijne Dierick; Christa Wildemauve; Claudine Godard; Patrick Butaye; Hein Imberechts; Patrick A D Grimont; Jean-Marc Collard
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  CTX-M-1- and CTX-M-15-type beta-lactamases in clinical Escherichia coli isolates recovered from food-producing animals in France.

Authors:  Danièle Meunier; Eric Jouy; Corinne Lazizzera; Marylène Kobisch; Jean-Yves Madec
Journal:  Int J Antimicrob Agents       Date:  2006-10-05       Impact factor: 5.283

6.  Invasive non-typhoidal salmonellosis in immunocompetent infants and children.

Authors:  Emmanouil Galanakis; Maria Bitsori; Sofia Maraki; Christina Giannakopoulou; George Samonis; Yiannis Tselentis
Journal:  Int J Infect Dis       Date:  2006-03-27       Impact factor: 3.623

7.  Impact of ciprofloxacin in the human-flora-associated (HFA) rat model: comparison with the HFA mouse model.

Authors:  Agnès Perrin-Guyomard; Jean-Michel Poul; Michel Laurentie; Pascal Sanders; A Haydée Fernández; Mary Bartholomew
Journal:  Regul Toxicol Pharmacol       Date:  2006-03-24       Impact factor: 3.271

8.  Antagonisms among isogenic strains of Escherichia coli in the digestive tracts of gnotobiotic mice.

Authors:  Y Duval-Iflah; P Raibaud; M Rousseau
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  R-plasmic transfer from Serratia liquefaciens to Escherichia coli in vitro and in vivo in the digestive tract of gnotobiotic mice associated with human fecal flora.

Authors:  Y Duval-Iflah; P Raibaud; C Tancrede; M Rousseau
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

10.  Cephalosporin-resistant Escherichia coli among summer camp attendees with salmonellosis.

Authors:  Guillem Prats; Beatriz Mirelis; Elisenda Miró; Ferran Navarro; Teresa Llovet; James R Johnson; Neus Camps; Angela Domínguez; Lluís Salleras
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

View more
  15 in total

1.  The role of horizontal gene transfer in the dissemination of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in an endemic setting.

Authors:  Yohei Doi; Jennifer M Adams-Haduch; Anton Y Peleg; Erika M C D'Agata
Journal:  Diagn Microbiol Infect Dis       Date:  2012-06-20       Impact factor: 2.803

2.  Fate of CMY-2-Encoding Plasmids Introduced into the Human Fecal Microbiota by Exogenous Escherichia coli.

Authors:  Valeria Bortolaia; Luca Guardabassi; Mehreen Anjum; Jonas Stenløkke Madsen; Joseph Nesme; Bimal Jana; Maria Wiese; Džiuginta Jasinskytė; Dennis Sandris Nielsen; Søren Johannes Sørensen; Anders Dalsgaard; Arshnee Moodley
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Resistance gene transfer during treatments for experimental avian colibacillosis.

Authors:  Alexandra Dheilly; Laëtitia Le Devendec; Gwenaëlle Mourand; Axelle Bouder; Eric Jouy; Isabelle Kempf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  Escherichia coli Probiotic Strain ED1a in Pigs Has a Limited Impact on the Gut Carriage of Extended-Spectrum-β-Lactamase-Producing E. coli.

Authors:  G Mourand; F Paboeuf; M A Fleury; E Jouy; S Bougeard; E Denamur; I Kempf
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae.

Authors:  Bärbel Stecher; Rémy Denzler; Lisa Maier; Florian Bernet; Mandy J Sanders; Derek J Pickard; Manja Barthel; Astrid M Westendorf; Karen A Krogfelt; Alan W Walker; Martin Ackermann; Ulrich Dobrindt; Nicholas R Thomson; Wolf-Dietrich Hardt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-09       Impact factor: 11.205

6.  Severe sepsis facilitates intestinal colonization by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and transfer of the SHV-18 resistance gene to Escherichia coli during antimicrobial treatment.

Authors:  Jun Guan; Shaoze Liu; Zhaofen Lin; Wenfang Li; Xuefeng Liu; Dechang Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

Review 7.  Allelic variation in Salmonella: an underappreciated driver of adaptation and virulence.

Authors:  Min Yue; Dieter M Schifferli
Journal:  Front Microbiol       Date:  2014-01-07       Impact factor: 5.640

8.  Human intestinal cells modulate conjugational transfer of multidrug resistance plasmids between clinical Escherichia coli isolates.

Authors:  Ana Manuel Dantas Machado; Morten O A Sommer
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

Review 9.  Strategies to minimize antibiotic resistance.

Authors:  Chang-Ro Lee; Ill Hwan Cho; Byeong Chul Jeong; Sang Hee Lee
Journal:  Int J Environ Res Public Health       Date:  2013-09-12       Impact factor: 3.390

10.  An In Vitro Chicken Gut Model Demonstrates Transfer of a Multidrug Resistance Plasmid from Salmonella to Commensal Escherichia coli.

Authors:  Roderick M Card; Shaun A Cawthraw; Javier Nunez-Garcia; Richard J Ellis; Gemma Kay; Mark J Pallen; Martin J Woodward; Muna F Anjum
Journal:  mBio       Date:  2017-07-18       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.